Disc Medicine reports positive Phase 3 APOLLO results for bitopertin in erythropoietic protoporphyria (EPP), with all primary and secondary endpoints met.

APOLLO builds on prior bitopertin research from BEACON, AURORA, and HELIOS across multiple phases, reinforcing the program’s trajectory.

Bitopertin, an oral GlyT1 inhibitor licensed from Roche and developed by Disc, aims to modulate heme biosynthesis to reduce PPIX buildup and improve light tolerance in EPP.

The company provides background, mentions strategic rights acquisition from Roche, and lists media and investor relations contacts.

Regulatory context notes that the FDA previously issued a Complete Response Letter due to uncertainty linking PPIX reduction to sunlight tolerance, but leadership changes and a flexible rare-disease review stance may help reconsideration.

The positive data comes in a supportive market backdrop, with equities signaling risk-on sentiment for biotech catalysts.

Analysts view the results as strongly supportive of approval, with some predicting a best-in-class profile and a multi-billion dollar market opportunity.

Disc Medicine’s stock traded near the lower end of its 52-week range before the data release and rallied toward annual highs on the news.

Bitopertin is not approved anywhere and Disc remains focused on hematologic diseases via heme biosynthesis and iron homeostasis pathways.

A webcast to discuss APOLLO topline results is scheduled for Monday, October 19, 2026, with registration on Disc Medicine’s website.

Disc reported about $717.7 million in cash and equivalents as of mid-2026, supporting operations into 2029 and the bitopertin program.

The combination of a clean Phase 3 outcome in a rare disease with no approved oral therapy, an NDA resubmission timeline, and favorable market conditions drove a dramatic one-day stock move.